These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17826371)

  • 1. Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of Thomas KL; Al-Khatib SM; Kelsey RC; Bush H; Brosius L; Velazquez EJ; Peterson ED; Gilliam FR
    Am J Cardiol; 2007 Sep; 100(6):924-9. PubMed ID: 17826371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
    Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure.
    Hernandez AF; Fonarow GC; Liang L; Al-Khatib SM; Curtis LH; LaBresh KA; Yancy CW; Albert NM; Peterson ED
    JAMA; 2007 Oct; 298(13):1525-32. PubMed ID: 17911497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF.
    Mehra MR; Yancy CW; Albert NM; Curtis AB; Stough WG; Gheorghiade M; Heywood JT; McBride ML; O'Connor CM; Reynolds D; Walsh MN; Fonarow GC
    Heart Rhythm; 2009 Dec; 6(12):1727-34. PubMed ID: 19959119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women and minorities are less likely to receive an implantable cardioverter defibrillator for primary prevention of sudden cardiac death.
    Mezu U; Ch I; Halder I; London B; Saba S
    Europace; 2012 Mar; 14(3):341-4. PubMed ID: 22071382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in the use of primary prevention and defibrillator therapy among blacks and women.
    Gauri AJ; Davis A; Hong T; Burke MC; Knight BP
    Am J Med; 2006 Feb; 119(2):167.e17-21. PubMed ID: 16443424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Referral Patterns for Primary Prophylaxis Implantable Cardioverter Defibrillator Therapy for an Urban US Population.
    Manheimer ED; Gonzalez C; Turk J; Krumerman AK; Kim SG; Gross JN; Palma EC; Grushko MJ; Fisher JD; Ferrick KJ
    Am J Cardiol; 2015 Oct; 116(8):1210-2. PubMed ID: 26320756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
    Marzec LN; Peterson PN; Bao H; Curtis JP; Masoudi FA; Varosy PD; Bradley SM
    JAMA Cardiol; 2017 May; 2(5):561-565. PubMed ID: 28122073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry.
    Ziaeian B; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW; Fonarow GC
    J Am Coll Cardiol; 2014 Aug; 64(8):797-807. PubMed ID: 25145524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in implantable cardioverter-defibrillator racial disparity: the importance of geography.
    Groeneveld PW; Heidenreich PA; Garber AM
    J Am Coll Cardiol; 2005 Jan; 45(1):72-8. PubMed ID: 15629377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization.
    Goldstein SA; Li S; Lu D; Matsouaka RA; Rymer J; Fonarow GC; de Lemos JA; Peterson E; Pokorney SD; Wang T; Al-Khatib SM
    Am J Cardiol; 2021 Jan; 138():26-32. PubMed ID: 33068540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction.
    LaPointe NM; Al-Khatib SM; Piccini JP; Atwater BD; Honeycutt E; Thomas K; Shah BR; Zimmer LO; Sanders G; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):146-51. PubMed ID: 21304098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients.
    Pokorney SD; Hellkamp AS; Yancy CW; Curtis LH; Hammill SC; Peterson ED; Masoudi FA; Bhatt DL; Al-Khalidi HR; Heidenreich PA; Anstrom KJ; Fonarow GC; Al-Khatib SM
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):145-51. PubMed ID: 25504649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.
    Hoang A; Shen C; Zheng J; Taylor S; Groh WJ; Rosenman M; Buxton AE; Chen PS
    Heart Rhythm; 2014 May; 11(5):849-55. PubMed ID: 24566233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure.
    Chia YMF; Teng TK; Tan ESJ; Tay WT; Richards AM; Chin CWL; Shimizu W; Park SW; Hung CL; Ling LH; Ngarmukos T; Omar R; Siswanto BB; Narasimhan C; Reyes EB; Yu CM; Anand I; MacDonald MR; Yap J; Zhang S; Finkelstein EA; Lam CSP
    Circ Cardiovasc Qual Outcomes; 2017 Nov; 10(11):. PubMed ID: 29150533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community.
    Narayanan K; Reinier K; Uy-Evanado A; Teodorescu C; Chugh H; Marijon E; Gunson K; Jui J; Chugh SS
    Circulation; 2013 Oct; 128(16):1733-8. PubMed ID: 24048201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.